These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 14624684)

  • 1. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
    Laterre PF; Wittebole X
    Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
    Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
    Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
    Scipione MR; Nogid B; Davanos E; DiGregorio RV
    Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
    McCoy C
    Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
    Farmer JC
    Crit Care Med; 2005 Oct; 33(10):2428-31. PubMed ID: 16215411
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, observational study of Xigris Use in the United States (XEUS).
    Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB;
    J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.